Trial results for the Phase 2 study (NCT03836066) investigating atezolizumab in combination with bevacizumab for first-line non-small cell lung cancer (NSCLC) were posted on ClinicalTrials.gov on 2025-12-04. The study reported a median progression-free survival (PFS) of 11.3 months in patients with locally advanced or metastatic high-intermediate tumour mutation burden NSCLC.
Background
Atezolizumab in combination with bevacizumab is being investigated as a first-line treatment for locally advanced or metastatic non-small cell lung cancer (NSCLC) patients with high-intermediate tumour mutation burden.
Trial design
The Phase 2 study (NCT03836066) was a multi-center trial that enrolled 41 participants. The trial investigated atezolizumab in combination with bevacizumab as first-line treatment for locally advanced or metastatic high-intermediate tumour mutation burden Non Small Cell Lung Cancer patients. The study aimed to examine the efficacy of this combination, measured by progression-free survival (PFS) according to RECIST version 1.1.
Key results
The trial reported on the efficacy of atezolizumab in combination with bevacizumab, specifically for progression-free survival (PFS).
- For the outcome titled "Efficacy of Atezolizumab in Combination With Bevacizumab - PFS" in the "Experimental: Atezolizumab plus Bevacizumab arm," the median progression-free survival was 11.3 months.
What this means
The reported median progression-free survival of 11.3 months for atezolizumab plus bevacizumab in this Phase 2 trial provides initial efficacy data for this combination in first-line locally advanced or metastatic high-intermediate tumour mutation burden Non Small Cell Lung Cancer. These findings contribute to the understanding of potential treatment options for this specific patient population.
Source
The information regarding these trial results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for study NCT03836066, titled "Atezolizumab Plus Bevacizumab in First Line NSCLC Patients," were posted on 2025-12-04 on clinicaltrials.gov.